

10/ 019,945

Welcome to STN International! Enter x:x

LOGINID:sssptal202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 SEP 09 CA/CAPLUS records now contain indexing from 1907 to the  
present  
NEWS 4 AUG 05 New pricing for EUROPATFULL and PCTFULL effective  
August 1, 2003  
NEWS 5 AUG 13 Field Availability (/FA) field enhanced in BEILSTEIN  
NEWS 6 AUG 18 Data available for download as a PDF in RDISCLOSURE  
NEWS 7 AUG 18 Simultaneous left and right truncation added to PASCAL  
NEWS 8 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Right  
Truncation  
NEWS 9 AUG 18 Simultaneous left and right truncation added to ANABSTR  
NEWS 10 SEP 22 DIPPR file reloaded  
NEWS 11 SEP 25 INPADOC: Legal Status data to be reloaded  
NEWS 12 SEP 29 DISSABS now available on STN  
NEWS 13 OCT 10 PCTFULL: Two new display fields added  
NEWS 14 OCT 21 BIOSIS file reloaded and enhanced  
NEWS 15 OCT 28 BIOSIS file segment of TOXCENTER reloaded and enhanced  
NEWS 16 NOV 24 MSDS-CCOHS file reloaded  
  
NEWS EXPRESS NOVEMBER 14 CURRENT WINDOWS VERSION IS V6.01c, CURRENT  
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 09:16:26 ON 03 DEC 2003

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 09:16:37 ON 03 DEC 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

10/ 019,945

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 2 DEC 2003 HIGHEST RN 622845-74-3  
DICTIONARY FILE UPDATES: 2 DEC 2003 HIGHEST RN 622845-74-3

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>  
Uploading 10019945s.str

L1 STRUCTURE UPLOADED

=> d l1  
L1 HAS NO ANSWERS  
L1 STR



G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful  
FULL SEARCH INITIATED 09:16:54 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - >1,000,000 TO ITERATE

< 35.6% PROCESSED 400000 ITERATIONS 53 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.43

FULL FILE PROJECTIONS: ONLINE \*\*INCOMPLETE\*\*  
BATCH \*\*INCOMPLETE\*\*  
PROJECTED ITERATIONS: EXCEEDS 1000000  
PROJECTED ANSWERS: EXCEEDS 112

L2 53 SEA SSS FUL L1

=> file caplus	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	148.55	148.76

FILE 'CAPLUS' ENTERED AT 09:17:46 ON 03 DEC 2003

10/ 019,945

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Dec 2003 VOL 139 ISS 23  
FILE LAST UPDATED: 2 Dec 2003 (20031202/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2

L3 13 L2

=> d l3 1- ibib abs hitstr

YOU HAVE REQUESTED DATA FROM 13 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:221654 CAPLUS

DOCUMENT NUMBER: 138:238029

TITLE: Preparation of ureas as vanilloid receptor (VR1) antagonists

INVENTOR(S): Rami, Harshad Kantilal; Thompson, Mervyn; Wyman, Paul Adrian

PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK

SOURCE: PCT Int. Appl., 57 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003022809	A2	20030320	WO 2002-GB4206	20020913
WO 2003022809	A3	20030717		



W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY,\* KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2001-22156 A 20010913  
GB 2001-30503 A 20011220  
GB 2001-30505 A 20011220  
GB 2001-30547 A 20011220

OTHER SOURCE(S): MARPAT 138:238029

GI



AB The title compds. [I; P, P1 = (hetero)aryl; R1, R2 = H, halo, alkyl, etc.; n = 0-3; p, q = 0-4; r = 1-3; s = 0-2], useful in medicine for the treatment and/or prophylaxis of pain, were prepd. Thus, reacting 2-bromophenyl isocyanate with (R)-1-(5-trifluoromethylpyridin-2-yl)-pyrrolidin-3-ylamine [claimed to be prepd. starting from 2-chloro-5-trifluoromethylpyridine and (3R)-3-(tert-butoxycarbonylamino)pyrrolidine; no data given] afforded (3R)-II. All compds., tested for vanilloid receptor (VR1) antagonist activity, had pKb > 6, preferred compds. having a pKb > 7.0.

IT 501952-15-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of ureas as vanilloid receptor (VR1) antagonists for treating pain)

RN 501952-15-4 CAPLUS

CN Urea, N-(3-methyl-5-cinnolinyl)-N'-[(3R)-1-[5-(trifluoromethyl)-2-pyridinyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN


ACCESSION NUMBER: 2003:133246 CAPLUS

DOCUMENT NUMBER: 138:170245

TITLE: Preparation of aminophthalazinones as kinase

inhibitors.  
 INVENTOR(S): Pulici, Maurizio  
 PATENT ASSIGNEE(S): Pharmacia Italia S.P.A., Italy  
 SOURCE: PCT Int. Appl., 103 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003014090	A1	20030220	WO 2002-EP8544	20020730
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003073692	A1	20030417	US 2001-922729	20010807
PRIORITY APPLN. INFO.:			US 2001-922729	A 20010807
OTHER SOURCE(S):		MARPAT 138:170245		
GI				



AB A method for treating diseases assocd. with altered protein kinase activity comprises administration of title compds. [I; Ra, Rb = H, (substituted) alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocycloalkyl; or 1 or Ra, Rb = H, (substituted) alkyl, the other = COR', CONHR', CO2R', SO2R'; R' = H, (substituted) alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; R1 = CHR4R5; R4, R5 = H, (substituted) alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; or R1 = NHR', NR'COR'', NR'CONHR'', NR'SO2R''; R'' = H, R'; R2 = H, (substituted) alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; R3 = halo, NO2, CO2H, cyano, (substituted) alkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; or R3 = COR', CONHR', SO2R', NR'R'', NR'COR'', NR'CONHR'', NR'SO2R''; m = 0-3] (no data). Thus, 6-nitrophthalide was refluxed 11 h with Br2 and H2O2 in H2O to give 6-nitro-3-bromo-3H-isobenzofuran-1-one. The latter in Et propionate at 70-75.degree. was treated with PPh3 in Et propionate followed by heating and stirring overnight to give (5-amino-3-oxo-1,3-dihydroisobenzofuran-1-yl)triphenylphosphonium bromide. The latter in CH2Cl2/trifluoroethanol/HOAc was stirred 9 h with 4-(4-formyl-3-methoxyphenoxy)butyryl aminomethylated resin followed by addn. of BH3.pyridine to give after 40 h [5-[2-methoxy-4-[3-(4-resin-benzylcarbamoxy)propoxy]benzylamino]-3-oxo-1,3-dihydroisobenzofuran-1-

yl]triphenylphosphonium bromide. This was stirred with pyridine-3-carboxaldehyde and Et<sub>3</sub>N in CH<sub>2</sub>Cl<sub>2</sub> for 20 h to give 4-[3-methoxy-4-[[3-oxo-1-(1-pyridin-3-ylmethylidene)-1,3-dihydroisobenzofuran-5-ylamino]methyl]phenoxy]-N-(4-resin-benzyl)butyramide. This was converted to N-(4-oxo-1-pyridin-3-ylmethyl-3,4-dihydrophthalazin-6-yl)benzamide. I are useful in the treatment of diseases caused by and/or assocd. with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, autoimmune diseases and neurodegenerative disorders.


IT 497254-73-6P 497254-86-1P 497254-99-6P  
 497255-12-6P 497255-25-1P 497255-38-6P  
 497255-51-3P 497255-64-8P 497255-77-3P  
 497255-91-1P 497256-04-9P 497256-17-4P  
 497256-33-4P 497256-53-8P 497256-66-3P  
 497256-79-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compd.; prepn. of aminophthalazinones as kinase inhibitors)


RN 497254-73-6 CAPLUS

CN Benzoic acid, 4-[[3,4-dihydro-4-oxo-6-[[[(3-pyridinylamino)carbonyl]amino]-1-phthalazinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 497254-86-1 CAPLUS


CN Urea, N-[1-[(4-chloro-3-fluorophenyl)methyl]-3,4-dihydro-4-oxo-6-phthalazinyl]-N'-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 497254-99-6 CAPLUS


CN Urea, N-[3,4-dihydro-1-[(2E)-3-(4-nitrophenyl)-2-propenyl]-4-oxo-6-phthalazinyl]-N'-3-pyridinyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 497255-12-6 CAPLUS

CN Urea, N-[3,4-dihydro-4-oxo-1-(3-thienylmethyl)-6-phthalazinyl]-N'-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 497255-25-1 CAPLUS

CN Urea, N-[3,4-dihydro-1-[(3-methoxyphenyl)methyl]-4-oxo-6-phthalazinyl]-N'-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 497255-38-6 CAPLUS

CN Urea, N-(3,4-dihydro-4-oxo-1-propyl-6-phthalazinyl)-N'-3-pyridinyl- (9CI)  
(CA INDEX NAME)



RN 497255-51-3 CAPLUS

CN Urea, N-[1-(3,3-dimethylbutyl)-3,4-dihydro-4-oxo-6-phthalazinyl]-N'-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 497255-64-8 CAPLUS

CN Urea, N-[3,4-dihydro-4-oxo-1-(3-phenylpropyl)-6-phthalazinyl]-N'-3-pyridinyl- (9CI) (CA INDEX NAME)




10/ 019,945




RN 497255-77-3 CAPLUS

CN Urea, N-[3,4-dihydro-4-oxo-1-(3-pyridinylmethyl)-6-phthalazinyl]-N'-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 497255-91-1 CAPLUS


CN Urea, N-[1-[(4-chlorophenyl)methyl]-3,4-dihydro-4-oxo-6-phthalazinyl]-N'-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 497256-04-9 CAPLUS


CN Urea, N-[1-[(4-cyanophenyl)methyl]-3,4-dihydro-4-oxo-6-phthalazinyl]-N'-3-pyridinyl- (9CI) (CA INDEX NAME)

10/ 019,945




RN 497256-17-4 CAPLUS

CN Urea, N-[1-[(3-fluorophenyl)methyl]-3,4-dihydro-4-oxo-6-phthalazinyl]-N'-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 497256-33-4 CAPLUS

CN Urea, N-[3,4-dihydro-1-[(3-methylphenyl)methyl]-4-oxo-6-phthalazinyl]-N'-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 497256-53-8 CAPLUS


CN Urea, N-[1-[(2,4-dichlorophenyl)methyl]-3,4-dihydro-4-oxo-6-phthalazinyl]-N'-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 497256-66-3 CAPLUS  
 CN Urea, N-[3,4-dihydro-4-oxo-1-(3-quinolinylmethyl)-6-phthalazinyl]-N'-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 497256-79-8 CAPLUS  
 CN Urea, N-[3,4-dihydro-4-oxo-1-[[2-(trifluoromethyl)phenyl]methyl]-6-phthalazinyl]-N'-3-pyridinyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 2002:965133 CAPLUS  
 DOCUMENT NUMBER: 138:39277

TITLE: Preparation of N-thiazolyl-N'-pyridyl ureas as antitumor agents

INVENTOR(S): Askew, Benny C.; De Morin, Frenel F.; Hague, Andrew; Laber, Ellen; Li, Aiwen; Liu, Gang; Lopez, Patricia; Nomak, Rana; Santora, Vincent; Tegley, Christopher; Yang, Kevin

PATENT ASSIGNEE(S): Amgen, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 129 pp., Cont.-in-part of U. S. Ser. No. 930,753.  
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002193405	A1	20021219	US 2002-77124	20020215
US 6645990	B2	20031111		
US 2002173507	A1	20021121	US 2001-930753	20010814
WO 2003070727	A1	20030828	WO 2003-US4537	20030213

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-225793P P 20000815  
US 2001-930753 A2 20010814  
US 2002-77124 A 20020215

OTHER SOURCE(S): MARPAT 138:39277  
GI



I

AB The title compds. [I; R15 = H, heterocyclyl, Ph, etc.; R16 = H, heterocyclylcarbonyl, alkylaminocarbonyl, etc.; R17 = halo, alkyl, cycloalkyl, etc.; provided only one of R15 and R16 = H] which are effective for prophylaxis and treatment of diseases, such as cell proliferation or apoptosis mediated diseases involving stroke, cancer and the like, were prepd. Thus, heating 2-phenyl-4-thiazolylcarbonylazide with 6-(3-methylpiperidin-1-ylmethyl)pyridin-2-ylamine in PhMe afforded the urea I [R15 = 3-methylpiperidin-1-ylmethyl; R16 = H; R17 = Ph] which showed cdk2/cyclin and cdk5/p25 kinase activity with IC50 of < 0.5 .mu.M.


IT 400774-22-3P 400774-24-5P 400774-25-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N-thiazolyl-N'-pyridyl ureas as antitumor agents)


RN 400774-22-3 CAPLUS

CN Urea, N-1,6-naphthyridin-2-yl-N'-[2-(4-pyridinyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)




RN 400774-24-5 CAPLUS

CN Urea, N-[2-(4-pyridinyl)-4-thiazolyl]-N'-(5,6,7,8-tetrahydro-6-propyl-1,6-naphthyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 400774-25-6 CAPLUS

CN Urea, N-(6-ethyl-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)-N'-[2-(4-pyridinyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)



L3 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:866687 CAPLUS

DOCUMENT NUMBER: 137:353013

TITLE: Thiazole derivatives and their use as cdk inhibitors, including combinations and pharmaceutical compositions

INVENTOR(S): Cooper, Christopher Blair; Helal, Christopher John; Sanner, Mark Allen

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: Eur. Pat. Appl., 32 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1256578	A1	20021113	EP 2002-253106	20020502
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2002338556	A2	20021127	JP 2002-132275	20020508
BR 2002001691	A	20030311	BR 2002-1691	20020513
US 2003078252	A1	20030424	US 2002-144403	20020513


PRIORITY APPLN. INFO.:

US 2001-290466P P 20010511

OTHER SOURCE(S):

MARPAT 137:353013

GI



AB The invention provides compds. thiazole derivs. I [wherein: R1 = (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, bicycloalkyl, bicycloalkenyl, heterobicycloalkyl, aryl, heteroaryl, or amino including cyclic amino; R3 = (un)substituted CONH, COO, CO(CH<sub>2</sub>)<sub>n</sub>, (CH<sub>2</sub>)<sub>n</sub>; R4 = as given for R1 except amino; n = 0-3; including pharmaceutically acceptable salts]. I are inhibitors of cyclin-dependent protein kinases (cdk), particularly cdk5, cdk2, and GSK-3. Pharmaceutical compns. and methods comprising compds. I are described, particularly for treating diseases and conditions comprising abnormal cell growth, such as cancer, and neurodegenerative diseases and conditions and those affected by dopamine neurotransmission. Also described are pharmaceutical compns. and methods comprising compds. I for treating or improving the following: male fertility and sperm motility problems, diabetes mellitus, impaired glucose tolerance, metabolic syndrome or syndrome X, polycystic ovary syndrome, adipogenesis and obesity, myogenesis and frailty (for example age-related decline in phys. performance), acute sarcopenia (for example, muscle atrophy and/or cachexia assocd. with burns, bed rest, limb immobilization, or major thoracic, abdominal, and/or orthopedic surgery), sepsis, hair loss, hair thinning, balding, and immunodeficiency. Approx. 90 specific compds. I are claimed, and the preps. of 5 of these and several intermediates are exemplified. For instance, 2-aminothiazole was lithiated and silylated, then re-lithiated and treated with cyclobutanone to give 1-(2-aminothiazol-5-yl)cyclobutanol. This alc. was hydrogenated to give 5-cyclobutylthiazol-2-ylamine, which was coupled with 6-quinolylacetic acid using T3P (1-propanephosphonic acid cyclic trimeric anhydride), to give title compd. II. The 5 exemplified compds. all had IC<sub>50</sub> values of < 50 .mu.M for inhibiting cdk5, cdk2, and GSK-3.beta. in vitro.


IT 474460-95-2P, 1-(5-Cyclobutylthiazol-2-yl)-3-(1,4-dioxo-1,2,3,4-tetrahydrophthalazin-5-yl)urea

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; prepn. of thiazole derivs. as cdk inhibitors)

RN 474460-95-2 CAPLUS

CN Urea, N-(5-cyclobutyl-2-thiazolyl)-N'-(1,2,3,4-tetrahydro-1,4-dioxo-5-phthalazinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:594630 CAPLUS

DOCUMENT NUMBER: 137:150266

TITLE: Naphthyridine compounds for treatment of mammalian diseases

INVENTOR(S): Semones, Marcus A.

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 39 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002060382	A2	20020808	WO 2002-US1474	20020118
WO 2002060382	A3	20020926		


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-262862P P 20010119

OTHER SOURCE(S): MARPAT 137:150266

GI



AB The present invention relates to naphthyridine compds. (I: R1 = aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclic alkyl, aroyl, alkanoyl; R2 = H, C1-10 alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic, heterocyclic alkyl, alkenyl, cycloalkenyl, alkynyl; R1 and R2 may be independently optionally substituted) and the treatment of mammalian diseases in which inappropriate, excessive or undesirable angiogenesis has occurred and/or where excessive Tie2 receptor kinase activity has occurred. Naphthyridine compds. have IC50 in the range of 1-104 nM, typically in the 700-104 nM range. For example, 3-(2,6-dichlorophenyl)-1,6-naphthyridin-2'-2-[N'-(1,1-dimethylethyl)urea] was prepd. in a yield of 36% (25 mg) by the reaction of 100 mg of 4-aminonicotinaldehyde and 217 mg of 2,6-dichlorophenylacetonitrile to obtain 191 mg of 3-(2,6-dichlorophenyl)-1,6-naphthyridin-2-amine, followed by the reaction of 51 mg of 3-(2,6-dichlorophenyl)-1,6-naphthyridin-2-amine obtained with 17 mg of tert-Bu isocyanate. A model of inflammatory angiogenesis are used to show that inhibition of Tie2 will stop the tissue destruction of excessive, inappropriate or undesirable proliferation of blood vessels.


IT 444880-63-1P 444880-64-2P 444880-65-3P  
444880-66-4P 444880-67-5P 444880-68-6P  
444880-69-7P 444880-70-0P 444880-71-1P  
444880-72-2P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP. (Preparation); USES (Uses)

(naphthyridine compds. for treatment of mammalian diseases characterized with undesirable angiogenesis)

RN 444880-63-1 CAPLUS


CN Urea, N-[3-(3,5-dimethylphenyl)-1,6-naphthyridin-2-yl]-N'-(tetrahydro-2H-pyran-2-yl)- (9CI) (CA INDEX NAME)




RN 444880-64-2 CAPLUS

CN Urea, N-[3-[5-(dimethylamino)-1,3,4-oxadiazol-2-yl]-1,6-naphthyridin-2-yl]-N'-(tetrahydro-2H-pyran-2-yl)- (9CI) (CA INDEX NAME)







RN 444880-65-3 CAPLUS  
CN Urea, N-(tetrahydro-2H-pyran-2-yl)-N'-[3-(3-thienyl)-1,6-naphthyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 444880-66-4 CAPLUS  
CN Urea, N-[3-[3,5-bis(trifluoromethyl)phenyl]-1,6-naphthyridin-2-yl]-N'-(tetrahydro-2H-pyran-2-yl)- (9CI) (CA INDEX NAME)



RN 444880-67-5 CAPLUS  
CN Urea, N-[3-(2-chloro-6-fluorophenyl)-1,6-naphthyridin-2-yl]-N'-(tetrahydro-2H-pyran-2-yl)- (9CI) (CA INDEX NAME)





RN 444880-68-6 CAPLUS  
CN Urea, N-[3-(2,5-dimethylphenyl)-1,6-naphthyridin-2-yl]-N'-(tetrahydro-2H-pyran-2-yl)- (9CI) (CA INDEX NAME)




RN 444880-69-7 CAPLUS

CN Urea, N-[3-(2-pyridinyl)-1,6-naphthyridin-2-yl]-N'-(tetrahydro-2H-pyran-2-yl) - (9CI) (CA INDEX NAME)





RN 444880-70-0 CAPLUS

CN Urea, N-[3-(2-methoxyphenyl)-1,6-naphthyridin-2-yl]-N'-(tetrahydro-2H-pyran-2-yl) - (9CI) (CA INDEX NAME)




RN 444880-71-1 CAPLUS

CN Urea, N-[3-(3,4-difluorophenyl)-1,6-naphthyridin-2-yl]-N'-(tetrahydro-2H-pyran-2-yl) - (9CI) (CA INDEX NAME)




RN 444880-72-2 CAPLUS  
 CN Urea, N-[3-(3-methylphenyl)-1,6-naphthyridin-2-yl]-N'-(tetrahydro-2H-pyran-2-yl)- (9CI) (CA INDEX NAME)



L3 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 2002:591913 CAPLUS  
 DOCUMENT NUMBER: 137:150215  
 TITLE: Cdk4 and/or Cdk6 inhibitors with biaryl ureas and their salts as antitumor agents  
 INVENTOR(S): Hatayama, Satoshi; Hayashi, Kyoko; Honma, Mitsuki; Takahashi, Ikuko  
 PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 194 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002220338	A2	20020809	JP 2001-18755	20010126
PRIORITY APPLN. INFO.:			JP 2001-18755	20010126
OTHER SOURCE(S):			MARPAT 137:150215	

GI



AB This invention relates to the general structures (I; Ar = N-contg. hetero arom. ring, X, Z = C, etc.; Y = CO, etc.; R1-R5 = H, etc.) and their salts as Cdk4 and/or Cdk6 inhibitors. I have antiproliferative effects on cancer cells and are potential antitumor agents. Formulation examples of I capsules, tablets, and injections were given.


IT 322686-07-7 322686-08-8 322686-09-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Cdk4 and/or Cdk6 inhibitors with biaryl ureas and their salts as antitumor agents)


RN 322686-07-7 CAPLUS

CN Urea, N-(5,6,7,8-tetrahydro-6-methyl-2,6-naphthyridin-3-yl)-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)




RN 322686-08-8 CAPLUS

CN Urea, N-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)-N'-[5,6,7,8-tetrahydro-6-(phenylmethyl)-2,6-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 322686-09-9 CAPLUS

CN Urea, N-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)-N'-[5,6,7,8-tetrahydro-7-(phenylmethyl)-2,7-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)



L3 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:323136 CAPLUS

DOCUMENT NUMBER: 137:93926

TITLE: Synthesis and Antiviral Evaluation of Some New Glycosylthioureas Containing a Quinazolinone Nucleus

AUTHOR(S): Saleh, Mohamed A.; Abdel-Megged, Mohamed F.; Abdo, Mohamed A.; Shokr, Abdel-Basset M.

CORPORATE SOURCE: Chemistry Department, Faculty of Science, Tanta University, Tanta, Egypt

SOURCE: Nucleosides, Nucleotides & Nucleic Acids (2002), 21(1), 93-106

CODEN: NNNAFY; ISSN: 1525-7770

PUBLISHER: Marcel Dekker, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 137:93926

AB A new synthesis of glycosylthioureas contg. a quinazolinone nucleus is described utilizing per-O-acetylglycopyranosylisothiocyanates and several aminoquinazolinones as starting compds. Structural proofs of these compds. are provided from elemental analyses, IR, <sup>1</sup>H and <sup>13</sup>C NMR spectra and mass spectra. The biol. activity of these compds. has been studied and show no activity against Human Immunodeficiency Virus (HIV) or against various tumor viruses.

IT 442637-38-9P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(synthesis, anti-HIV, and antitumor evaluation of some new glycosylthioureas contg. a quinazolinone nucleus)

RN 442637-38-9 CAPLUS

CN Thiourea, N-(4-oxo-2-phenyl-3(4H)-quinazolinyl)-N'-(2,3,4,6-tetra-O-acetyl-beta.-D-glucopyranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 442637-33-4P 442637-43-6P 442637-54-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(synthesis, anti-HIV, and antitumor evaluation of some new glycosylthioureas contg. a quinazolinone nucleus)

RN 442637-33-4 CAPLUS

CN Thiourea, N-(3,4-dihydro-2-methyl-4-oxo-3-phenyl-6-quinazolinyl)-N'-(2,3,4,6-tetra-O-acetyl-.beta.-D-glucopyranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 442637-43-6 CAPLUS

CN Thiourea, N-(1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl)-N'-(2,3,4,6-tetra-O-acetyl-.beta.-D-glucopyranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 442637-54-9 CAPLUS

CN Thiourea, N-.beta.-D-glucopyranosyl-N'-(4-oxo-2-phenyl-3(4H)-quinazolinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 2002:240759 CAPLUS  
 DOCUMENT NUMBER: 136:279469  
 TITLE: Preparation of quinoline and quinazoline derivatives as farnesyl transferase inhibitors for treatment of tumors and proliferative diseases  
 INVENTOR(S): Angibaud, Patrick Rene; Venet, Marc Gaston; Pilatte, Isabelle Noelle Constance  
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.  
 SOURCE: PCT Int. Appl., 66 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002024682	A1	20020328	WO 2001-EP10867	20010918
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1322635	A1	20030702	EP 2001-974271	20010918
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AU 2001093826	A5	20020402	AU 2001-93826	20020402
US 2003203904	A1	20031030	US 2003-381363	20030324
PRIORITY APPLN. INFO.:				
			EP 2000-203365	A 20000925
			WO 2001-EP10867	W 20010918

OTHER SOURCE(S): MARPAT 136:279469  
 GI



AB Title compds. I [wherein m and n = independently 0-5; q = 0-3; Y1Y2 = C:N or C:CR9; C9 = H, halo, CN, (cyclo)alkyl, hydroxyalkyl, alkoxy(alkyl), aminoalkyl, (amino)alkenyl, (amino)alkynyl, halocarbonyl, hydroxycarbonyl, alkoxy(alkyl), aryl, (un)substituted amino or carbamoyl, etc.; R1 and R2 = independently azido, OH, halo, CN, NO2, trihalomethyl, alkoxy, aryloxy, heterocycloxy, alkylthio, or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, carbamoyl, amino, sulfamoyl, etc.; or R1R2 = OCH2O, OCH2CH2O, OCH:CH, OCH2CH2, OCH2CH2CH2, CH:CHCH:CH; R3 = H, halo, CN, alkenyl, alkynyl, hydroxycarbonyl, alkoxy(alkyl), aryl, heterocyclyl, alkoxy, alkylthio, (un)substituted (cyclo)alkyl or amino, etc.; R4 = (un)substituted imidazolyl, triazolyl, or pyridyl; R5 = CN, OH, halo, alkenyl, alkynyl, hydroxycarbonyl, alkoxy(alkyl), or (un)substituted (cyclo)alkyl, alkoxy, amino, or carbamoyl, etc.; R7 = halo or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, alkylthio, carboxy, carbamoyl, acyl(amino), etc.; or pharmaceutically acceptable salts, N-oxides, or stereochem. isomeric forms thereof] were prepd. For example, N-[2-(3-chlorobenzoyl)-4-(4-chlorobenzoyl)phenyl]acetamide was cyclized with NH3 in i-PrOH to give (4-chlorophenyl)[4-(3-chlorophenyl)-2-methyl-6-quinazolinyl]methanone (36%). Addn. of 1-methyl-1H-imidazole in the presence of BuLi and SiEt3Cl in THF afforded II (40%). I have potent farnesyl transferase inhibitory effect and are useful for inhibiting proliferative diseases and growth of tumors expressing an activated ras oncogene (no data).

IT 405550-33-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(farnesyl transferase inhibitor; prepn. of quinoline and quinazoline derivs. as farnesyl transferase inhibitors for treatment of tumors and proliferative diseases)

RN 405550-33-6 CAPLUS

CN Thiourea, N-[4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-2-quinazolinyl]-N'-3-pyridinyl- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:142704 CAPLUS

DOCUMENT NUMBER: 136:200177

TITLE: Preparation of diheteroaryl ureas as antitumor agents

INVENTOR(S): Santora, Vent; Askew, Benny; Ghose, Arup; Hague, Andrew; Kim, Tae Seong; Laber, Ellen; Li, Aiwen; Lian, Brian; Liu, Gang; Norman, Mark Henry; Smith, Leon; Tasker, Andrew; Tegley, Christopher; Yang, Kevin

PATENT ASSIGNEE(S): Amgen Inc., USA

SOURCE: PCT Int. Appl., 371 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002014311	A2	20020221	WO 2001-US25472	20010815
WO 2002014311	A3	20020919		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2001084909	A5	20020225	AU 2001-84909	20010815
---------------	----	----------	---------------	----------

EP 1309589	A2	20030514	EP 2001-964009	20010815
------------	----	----------	----------------	----------



R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.: US 2000-225793P P 20000815

WO 2001-US25472 W 20010815

OTHER SOURCE(S): MARPAT 136:200177

GI



AB The title compds. [I; A1-A6 = CH<sub>2</sub>, CH, C, O, S, Nh, N; X and Z taken together to form a N atom contg. ring; Y = NHCO(CH<sub>2</sub>)<sub>p</sub>, CH<sub>2</sub>CO<sub>2</sub>, NHSO<sub>2</sub>CH<sub>2</sub>, NHCO<sub>2</sub>, NHCONR<sub>6</sub>(CH<sub>2</sub>)<sub>r</sub>; R<sub>2</sub> = alkylaminoalkynyl, cycloalkenylalkynyl, phenylalkynyl, etc.; p = 1-2; q = 0-1; r = 0-3; R<sub>6</sub> is not defined] which are effective for prophylaxis and treatment of diseases, such as cell proliferation or apoptosis mediated diseases involving stroke, cancer and the like, were prepd. Thus, treating 3-(3-pyridyl)-4-thiazolylcarbonylazide in PhMe with a few drops of H<sub>2</sub>O afforded the urea II which showed cdk2/cyclin and cdk5/cyclin kinase activity with IC<sub>50</sub> of < 50 .mu.M.


IT 400774-22-3P 400774-24-5P 400774-25-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of diheteroaryl ureas as antitumor agents)


RN 400774-22-3 CAPLUS

CN Urea, N-1,6-naphthyridin-2-yl-N'-[2-(4-pyridinyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)




RN 400774-24-5 CAPLUS

CN Urea, N-[2-(4-pyridinyl)-4-thiazolyl]-N'-(5,6,7,8-tetrahydro-6-propyl-1,6-naphthyridin-2-yl)- (9CI) (CA INDEX NAME)




RN 400774-25-6 CAPLUS

CN Urea, N-(6-ethyl-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)-N'-[2-(4-pyridinyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)



L3 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 2001:727667 CAPLUS  
 DOCUMENT NUMBER: 136:183778  
 TITLE: One-pot quinazolin-4-ylthiourea synthesis via  
 N-(2-cyanophenyl)benzimidoyl isothiocyanate  
 AUTHOR(S): Fathalla, W.; Cajan, M.; Marek, J.; Pazdera, P.  
 CORPORATE SOURCE: Dep. Org. Chem., Faculty Science, Masaryk Univ., Brno,  
 Czech Rep.  
 SOURCE: Molecules [online computer file] (2001), 6(7), 588-602  
 CODEN: MOLEFW; ISSN: 1420-3049  
 URL: <http://www.mdpi.org/molecules/papers/60700588.pdf>  
 PUBLISHER: Molecular Diversity Preservation International  
 DOCUMENT TYPE: Journal; (online computer file)  
 LANGUAGE: English  
 AB 1-Substituted-3-(2-phenylquinazolin-4-yl) thioureas were produced by an  
 intramol. cycloaddn. reaction of 1-substituted-3-[(2-  
 cyanophenylimino)phenylmethyl] thioureas. These compds. in turn were  
 prepd. by the reaction of N-(2-cyanophenyl)benzimidoyl isothiocyanate with  
 primary amines. The structures were confirmed by FTIR, <sup>1</sup>H-NMR, <sup>13</sup>C-NMR,  
 mass spectroscopy and x-ray crystallog.  
 IT 400053-16-9P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of (phenylquinazolinyl) thioureas by intramol. cycloaddn.  
 reaction of [(cyanophenylimino)phenylmethyl] thioureas)  
 RN 400053-16-9 CAPLUS  
 CN Thiourea, N-(2-phenyl-4-quinazolinyl)-N'-2-pyridinyl- (9CI) (CA INDEX  
 NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 2001:719183 CAPLUS  
 DOCUMENT NUMBER: 136:37266  
 TITLE: Complexation-Induced Unfolding of Heterocyclic Ureas.

Simple Foldamers Equilibrate with Multiply  
Hydrogen-Bonded Sheetlike Structures

AUTHOR(S): Corbin, Perry S.; Zimmerman, Steven C.; Thiessen, Paul  
A.; Hawryluk, Natalie A.; Murray, Thomas J.

CORPORATE SOURCE: Department of Chemistry, University of Illinois,  
Urbana, IL, 61801, USA

SOURCE: Journal of the American Chemical Society (2001),  
123(43), 10475-10488  
CODEN: JACSAT; ISSN: 0002-7863

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The synthesis and conformational studies of heterocyclic ureas (amides)  
N,N'-Di-2-pyridylurea (I), 2,7-Dipentanoylamido-1,8-naphthyridine (II),  
N-Butyl-N'-(1,8-naphthyridin-2-yl)urea (III), N-Butyl-N'-(4-methylpyridin-  
2-yl)urea (IV), 2-Pentanoylamido-1,8-naphthyridine (V),  
Bis-2,7-(3-(3,4,5-tridodecyloxyphenyl)uryl)-1,8-naphthyridine (VI), and  
N,N'-Di-((5,7-dipropyl-(1,8-naphthyridin))-2-yl)urea (VII) and their  
concn.-dependent unfolding to form multiply hydrogen-bonded complexes are  
described. Ureas I and VII were prepd. by reacting 2-aminopyridine and  
aminonaphthyridine, resp., with triphosgene and 4-(dimethylamino)pyridine  
(DMAP). Heterocyclic ureas III and IV, were prepd. by treating their  
corresponding amino precursors with butylisocyanate, whereas bisureido  
naphthyridines VI was prepd. by heating 2,7-diamino-1,8-naphthyridine (13)  
with butylisocyanate and 3,4,5-tridodecyloxyphenyl isocyanate, resp. The  
hydrogen-bonding modules II and V were synthesized. X-ray crystallog.  
analyses were performed on ureas I and III, indicating that these ureas  
are intramolecularly hydrogen-bonded in the solid state. Moreover,  
detailed <sup>1</sup>H NMR soln. studies of indicate that similar folded structures  
form in chloroform. In addn., naphthyridinylureas III and VII unfold and  
dimerize by forming four hydrogen bonds at high concns., and ureas I and  
IV unfold in the presence of their hydrogen-bonding complements, amides II  
and V, to form complexes with three and four hydrogen bonds, resp.  
Likewise, the mixing of VI and VII results in a mutual unfolding and  
formation of a robust, sheetlike, sextuply hydrogen-bonded complex. The  
hydrogen-bonding modules described are useful building blocks for  
self-assembly, and the unfolding process represents a very primitive  
mimicry of the helix-to-sheet transition shown by peptides and potentially  
shown by the hypothetical naphthyridinylurea.

IT 380441-61-2

RL: FMU (Formation, unclassified); PEP (Physical, engineering or chemical  
process); PRP (Properties); PYP (Physical process); FORM (Formation,  
nonpreparative); PROC (Process)

(crystallog. and NMR spectroscopy studies of conformational unfolding  
of heterocyclic ureas)

RN 380441-61-2 CAPLUS


CN Urea, N,N'-bis(5,7-dipropyl-1,8-naphthyridin-2-yl)-, compd. with  
N,N''-1,8-naphthyridine-2,7-diylbis[N'-[3,4,5-tris(dodecyloxy)phenyl]urea]  
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 380441-54-3

CMF C94 H162 N6 O8

PAGE 1-A




PAGE 1-B

—O—(CH<sub>2</sub>)<sub>11</sub>—Me—O—(CH<sub>2</sub>)<sub>11</sub>—Me

CM 2

CRN 269063-80-1

CMF C29 H36 N6 O



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

REFERENCE COUNT: 68 THERE ARE 68 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 2001:518623 CAPLUS  
 DOCUMENT NUMBER: 135:313150  
 TITLE: 1,3-Biarylureas as selective non-peptide antagonists  
 of the orexin-1 receptor  
 AUTHOR(S): Porter, R. A.; Chan, W. N.; Coulton, S.; Johns, A.;  
 Hadley, M. S.; Widdowson, K.; Jerman, J. C.; Brough,  
 S. J.; Coldwell, M.; Smart, D.; Jewitt, F.; Jeffrey,  
 P.; Austin, N.  
 CORPORATE SOURCE: New Frontiers Science Park North, GlaxoSmithKline  
 Pharmaceuticals, Harlow, Essex, CM19 5AW, UK  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2001),  
 11(14), 1907-1910  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier Science Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English


AB This communication reports SARs for the first orexin-1 receptor antagonist series of 1-aryl-3-quinolin-4-yl and 1-aryl-3-naphthyridin-4-yl ureas. One of these compds., 31 (SB-334867), has excellent selectivity for the orexin-1 receptor, blood-brain barrier permeability and shows in vivo activity following i.p. dosing.

IT 367953-08-0 367953-09-1 367953-12-6  
367953-13-7

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
(1,3-Biarylureas as selective non-peptide antagonists of orexin-1 receptor)


RN 367953-08-0 CAPLUS

CN Urea, N-(1-methyl-1H-indol-5-yl)-N'-4-quinazolinyl- (9CI) (CA INDEX NAME)




RN 367953-09-1 CAPLUS

CN Urea, N-(1-methyl-1H-indol-5-yl)-N'-1,5-naphthyridin-4-yl- (9CI) (CA INDEX NAME)



RN 367953-12-6 CAPLUS


CN Urea, N-(2-methyl-6-benzoxazolyl)-N'-1,6-naphthyridin-4-yl- (9CI) (CA INDEX NAME)



RN 367953-13-7 CAPLUS

10/ 019,945



CN Urea, N-(2-methyl-6-benzoxazolyl)-N'-1,8-naphthyridin-4-yl- (9CI) (CA  
INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN  
ACCESSION NUMBER: 2001:78363 CAPLUS  
DOCUMENT NUMBER: 134:147614  
TITLE: Preparation of N,N'-biarylurea derivatives as  
inhibitors of cyclin-dependent kinases (Cdk4 and Cdk6)  
INVENTOR(S): Hayama, Takashi; Hayashi, Kyoko; Honma, Mitsutaka;  
Takahashi, Ikuko  
PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan  
SOURCE: PCT Int. Appl., 460 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001007411	A1	20010201	WO 2000-JP4991	20000726
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 2001106673	A2	20010417	JP 2000-274175	20000726
EP 1199306	A1	20020424	EP 2000-949909	20000726
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
PRIORITY APPLN. INFO.:			JP 1999-211384	A 19990726
			WO 2000-JP4991	W 20000726
OTHER SOURCE(S):			MARPAT 134:147614	
GI				



AB N-(hetero)aryl-N'-heterocyclylurea derivs. represented by general formula (I) [wherein Ar represents a nitrogenous heterocyclic arom. group such as (un)substituted pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, pyrrolyl, imidazolyl, indolyl, isoindolyl, quinolyl, isoquinolyl, benzothiazolyl, or benzoxazolyl; X and Z each represents C or N or together with R1 or R2 and/or R3 represent CH or N; Y represents CO, SO, or SO<sub>2</sub>; R1 represents hydrogen, (un)substituted lower alkyl, Y3-W2-Y4-R5, etc.; wherein R5 = H, (un)substituted lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, aryl, imidazolyl, isoxazolyl, isoquinolyl, isoindolyl, indazolyl, indolyl, indolidinyl, isothiazolyl, ethylenedioxyphenyl, oxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, quinoxalinyl, quinolyl, etc.; W2 = single bond, O, S, SO, SO<sub>2</sub>, N-(un)substituted NH, SO<sub>2</sub>NH, NHSO<sub>2</sub>NH, NHSO<sub>2</sub>, CONH, NHCO, NHCONH, NHCO<sub>2</sub>, etc.; Y3, Y4 = single bond, linear or branched lower alkylene; R2 and R3 each represents hydrogen, lower alkyl or alkoxy, or Y3-W2-Y4-R5 (Y3, W2, Y4, R5 = same as above), or one of R2 and R3 together with R1 and X forms cyclohexane, cyclopentane, piperidine, 3,4,5,6-tetrahydro-1,3-oxazine, tetrahydrothiopyran, pyrrolidine, tetrahydrothiofuran, oxazolidine ring, etc.; R4 and R5 represent H, halo, OH, amino, or Y3-W2-Y4-R5 (Y3, W2, Y4, R5 = same as above)] or salts thereof are prepd. The compds. (e.g. II) have a remarkable proliferation-inhibitory effect on tumor cells. A Cdk4 and/or Cdk6 inhibitor for use in the therapy of malignant tumor can hence be provided. II showed IC<sub>50</sub> of 0.061 and 0.019  $\mu$ M against cyclin-D1-Cdk4 and cyclin-D2-Cdk4, resp., vs. 0.36 and 0.056  $\mu$ M, resp., for (+-)-flavopiridol, and inhibited the proliferation of HCT116 and MKN-1 cells with IC<sub>50</sub> of 0.013 and 0.10  $\mu$ M, resp., vs. 0.15 and 0.87  $\mu$ M, resp., for (+-)-flavopiridol. Pharmaceutical formulations contg. I were prepd.

IT 322686-07-7P 322686-08-8P 322686-09-9P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N-(hetero)aryl-N'-heterocyclylurea derivs. as inhibitors of cyclin-dependent kinases (Cdk4 and Cdk6) and antitumor agents)


RN 322686-07-7 CAPLUS

CN Urea, N-(5,6,7,8-tetrahydro-6-methyl-2,6-naphthyridin-3-yl)-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)






RN 322686-08-8 CAPLUS  
 CN Urea, N-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)-N'-  
 [5,6,7,8-tetrahydro-6-(phenylmethyl)-2,6-naphthyridin-3-yl]- (9CI) (CA  
 INDEX NAME)



RN 322686-09-9 CAPLUS  
 CN Urea, N-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)-N'-  
 [5,6,7,8-tetrahydro-7-(phenylmethyl)-2,7-naphthyridin-3-yl]- (9CI) (CA  
 INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

10/ 019,945

(FILE 'HOME' ENTERED AT 09:16:26 ON 03 DEC 2003)

FILE 'REGISTRY' ENTERED AT 09:16:37 ON 03 DEC 2003

L1 STRUCTURE UPLOADED

L2 53 S L1 FUL

FILE 'CAPLUS' ENTERED AT 09:17:46 ON 03 DEC 2003

L3 13 S L2

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

59.80

208.56

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-8.46

-8.46

STN INTERNATIONAL LOGOFF AT 09:18:47 ON 03 DEC 2003